In utero exposure to endocrine disrupting chemicals, micro-RNA profiles, and fetal growth: a pilot study protocol by Larose, Tricia L. et al.
[page 62]                                                [Journal of Public Health Research 2019; 8:1550]                                    
                                Journal of Public Health Research 2019; volume 8:1550
In utero exposure to endocrine disrupting chemicals, micro-RNA profiles,and fetal growth: a pilot study protocol
Tricia L. Larose,1,2 Pål Sætrom,1,3,4,5 Marit P. Martinussen,3 Håkon Skogseth,6
Torkjel M. Sandanger,7 Ghislaine Scélo,8 Cliona M. McHale,9 Geir W. Jacobsen,2
Martyn T. Smith9
1K.G. Jebsen Center for Genetic Epidemiology, Faculty of Medicine and Health Sciences, Norwegian
University of Science and Technology, Trondheim, Norway; 2Department of Public Health and Nursing,
Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim,
Norway; 3Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences,
Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Computer Science,
Faculty of Information Technology and Electrical Engineering, Norwegian University of Science and
Technology, Trondheim, Norway; 5Bioinformatics core facility – BioCore, Faculty of Medicine and Health
Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 6Biobank 1, St. Olavs
University Hospital, Trondheim, Norway; 7Department of Community Medicine, Faculty of Health Sciences,
UiT-the Arctic University of Norway, Tromsø, Norway; 8Genetic Epidemiology Group, Section of Genetics,
International Agency for Research on Cancer, World Health Organization, Lyon, France; 9Division of
Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA
Abstract
Background: The developing fetus is particularly vulnerable to
the effects of endocrine disrupting chemicals (EDCs). Molecular
fingerprints of EDCs can be identified via microRNA (miRNA)
expression profiles and may be etiologically implicated in the
developmental origin of disease (DOHaD).
Methods/design: This pilot study includes pregnant women at
high risk (smoking at conception), and low risk (non-smoking at
conception) for SGA birth (birthweight<10th percentile for gesta-
tional age). We have randomly selected 12 mothers (3 high-risk
SGA birth, 3 low-risk SGA birth, 3 high-risk non-SGA birth, 3
low-risk non-SGA birth), with EDC measurements from gestation-
al week 17. All offspring are female. We aim to test the stability of
our samples (maternal serum, cord blood, placenta tissue), observe
the differential expression of miRNA profiles over time (gestation-
al weeks 17, 25, 33, 37, birth), and study the consistency between
maternal EDC measures and miRNA expression profiles across
our repeated measures.
Expected impact of the study for Public Health: Results from
this pilot study will inform the development of a larger cohort
wide analysis, and will impact the current state of knowledge in
the fields of public health, epigenetics, and the DOHaD.
Introduction
The exposome refers to a cumulative measure of environmen-
tal exposures and associated biological responses from the prena-
tal period onward.1,2 Cumulative environmental exposures are
challenging to measure due in part to the short half-life of many
chemicals, as well as transient exposure levels.3 However, certain
environmental exposures such as persistent organic pollutants
(POPs) and tobacco smoke leave behind molecular fingerprints in
the form of epigenetically modified microRNA (miRNA) expres-
sion profiles.3 miRNAs are involved in many important biological
mechanisms including cell differentiation,4 cell apoptosis,5 and
development of individual tissues and organs;6 the latter being par-
ticularly relevant to in utero fetal programming and epigenetic pre-
disposition of disease.7,8 Increasing evidence suggests that circu-
lating miRNAs can be used as clinical biomarkers for diagnosis.
For example, in women with preeclampsia, distinct miRNA
expression profiles have been found in maternal serum and placen-
tal tissue,9 whereas environmental exposures such as organochlo-
rine pesticides10 and tobacco smoke11 have been associated with
altered miRNA expression in cord blood. At the same time,
miRNA expression in the placenta of growth restricted fetuses
does not always correspond with maternal serum miRNA expres-
sion.12 Taken together, these results suggest that miRNAs found in
placenta, maternal serum, and cord blood may be novel responders
to in utero environmental exposures. However, the biological
mechanisms by which in utero exposures effect fetal growth
indices, impact childhood outcomes, and influence the develop-
mental origin of adult disease remains unclear.9 An increasing
body of evidence suggests that in utero exposure to endocrine dis-
rupting chemicals (EDCs) may have consequential effects on the
Significance for public health
This research focuses on the developmental origin of disease with particular
emphasis on maternal exposure to endocrine disrupting chemicals during
pregnancy and fetal growth by examining microRNA profiles in maternal
serum, placenta tissue, and cord blood. Pregnant mothers and offspring are
the most vulnerable populations affected by environmental exposures
including exposure to pesticides, metals, and contaminants in food. Results
from our pilot study will inform a larger project proposal that will look not
only at epigenetic modifications and fetal development, but also the epige-
netic effects on longer term neurodevelopmental and metabolic outcomes in
childhood and early adulthood.
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epigenome of the developing fetus through to childhood.13,14 Ours
is the first study to consider the miRNA expression profiles across
five time-points in pregnancy (17, 25, 33, 37 weeks, birth) and
across bio-samples (maternal serum, cord blood, placenta tissue). 
Materials and Methods
Cohort description
The current pilot study utilizes Norwegian data and bio-sam-
ples from the Scandinavian Successive Small for Gestational Age
Births Study (the SGA Study) originally funded by the US
National Institute of Child Health and Human Development.15
Participant recruitment occurred over a 27-month period from
1986 to 1988. The SGA Study is a prospective birth cohort of
Norwegian and Swedish mother-child pairs with comprehensive
data on various maternal factors (e.g. tobacco smoking, diet, stress,
environmental pollutants) and fetal growth, size at birth, as well as
later bio-psycho-social development of offspring. A total of
n=1009 Norwegian mother-child pairs are included in the cohort.
Of these births, n=194 were term born SGA (cases), and n=815
were term born non-SGA (controls). SGA birth is defined as
infants with birth weight below the 10th percentile for gestational
age. The follow-up protocol included four comprehensive prenatal
visits including collection and storage (-80°C) of maternal serum
samples, a detailed neonatal offspring examination, collection and
storage (-80°C) of cord blood samples, and complete examination
of the placenta. Placenta tissue samples were collected, formalin
fixed, and embedded in paraffin for later examination. The current
pilot study includes 12 mother-child pairs from the Norwegian arm
of the SGA Study.
Participant selection for pilot study
Twelve Norwegian mother-child pairs have been randomly
selected within risk strata for SGA birth. Criteria for inclusion
were: full range of endocrine disrupting chemicals previously
measured in maternal serum at gestational week 17; serum samples
available for miRNA analysis from gestational weeks 17, 25, 33,
and 37; and cord blood samples available for miRNA analysis.
Placental tissue samples from one of the twelve selected mother-
child pairs are also included for miRNA analysis. All offspring
were female to reduce possible confounding and/or environmental
interaction by offspring sex.13 Participants were further selected
for SGA birth and non-SGA birth, as well as high risk for SGA
birth (reported current smoking at conception), and low risk for
SGA birth (reported non-smoking at conception) (Figure 1).
Placenta sample selection
As per the original SGA Study design, the full placenta was
collected at term birth for histopathological examination. Tissue
samples from four distinct regions of each placenta were collected
from every participant (umbilical cord, peripheral membrane on
the fetal side, central tissue, and tissue from the maternal side). An
additional tissue sample was collected from any pathological find-
ing. Despite the 30-year history of this birth cohort, the sampling
strategy employed at the inception of the SGA study is still in-line
with contemporary scientific opinion on the optimal sample collec-
tion procedures for placental research,16 thus speaking to the scien-
tific rigor upon which this birth cohort was built. Previous research
showed differential gene expression between intra-individual sam-
pling sites in human placenta at term,17 as well as systematic dif-
ferences in gene expression between maternal, fetal and intermedi-
ate layers of the human placentas from successful full-term preg-
nancies.18 Taking this into account, this pilot study will look at
miRNA expression in tissue samples from four distinct reasons of
one placenta from one mother as opposed to single tissue samples
from single regions for multiple mothers. Given the historical
nature of these samples, our first priority is to test the integrity of
our placenta samples for further use in a cohort wide analysis, and
we believe our proposed intra-individual analysis will provide
meaningful site-specific and sample-specific information.
Measuring maternal serum EDCs
Measurement of a comprehensive set of endocrine disrupting
chemicals (EDCs) is available for a sub-set of participating moth-
ers from the SGA Study.13,14 Analyses of maternal serum per- and
polyfluoroalkyl substances (PFAS) and organocholoride (OC) con-
centrations in maternal serum collected during the 2nd trimester
(gestational week 17-20) will be used in this pilot study. 
Measuring PFAS 
PFAS analyses were performed at the Norwegian Institute for
Air Research, Tromsø, Norway (NILU). Maternal serum samples
were quantified for two target analytes including perfluorooc-
tanoate (PFOA) and perfluorooctane sulfonate (PFOS). Detailed
information about the sample preparation, extraction method, ana-
lytical method, reagents and instrumentation has been previously
reported.19,20 PFAS concentrations were determined using sonica-
tion-facilitated liquid-liquid extraction, activated ENVI-carb
clean-up,21 and analyzed by ultrahigh pressure liquid chromatogra-
phy triple-quadruple mass-spectrometry (UHPLC-MS/MS).
Participation in the AMAP Ring Test ensures that the uncertainties
of the analysis are within ± 15-20% of the assigned values.22
Measuring OCs
The OC analyses were performed at the Institut National de
Sante ́ Publique du Quebec, Centre Toxicologie, Quebec. Several
OCs were measured, including hexachlorobenzene (HCB), oxy-
chlordane, poly- chlorinated biphenyl (PCB) 52, 101, 118, 153, 156,
170, and 180, p,p’-dichlorodiphenyldichloroehylene (p,p’- DDE),
p,p’-dichlorophenyltrichloroethane (p,p’-DDT), β- hexachlorohexa-
ne (β-HCH) and trans-nonachlor (t-NC). In short, 0.5-1 mL serum
sample was extracted using hexane (2×6 mL), ethanol (2 mL) and
saturated ammonium sulphate solution (2 mL). This method is a
slight modification of the one described by Sandanger et al.,23 where
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Figure 1. Participants sample selection for pilot study.
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the samples were cleaned using 1 g of activated fluorisil on an auto-
mated liquid handler system before GC-MS analysis.24
Measuring miRNAs
Total RNA isolation 
Total RNA will be isolated from 200 μL plasma by using the
QIAGEN miRNeasy serum/serum kit, as previously described.25
Briefly, the kit uses phenol-chloroform extraction to isolate RNA
from DNA and proteins. A spin column is then used to separate
RNA from organic contaminants and high-quality total RNA is
eluted from the column into RNase free water. RNA quality and
presence of small RNAs will be assessed by using the Eukaryote
total RNA pico assay on the 2100 Bioanalyzer. In contrast to total
RNA from cells, ribosomal RNA (rRNA) is depleted in cell-free
serum, so sample quality will be determined by detecting the pres-
ence of a small RNA peak and depletion of 18S and 28S rRNA
peaks in the Bioanalyzer trace.
miRNA sequencing
Total RNA will be used to prepare each sample for sequencing
using the NEXTflex small RNA Seq Kit. We will use standard proto-
cols that include spike-in RNAs for normalization and all work will be
performed at the Norwegian University of Science and Technology
(NTNU) Genomics Core Facility (GCF). This facility has extensive
expertise in performing both the capture and next generation sequenc-
ing via the lllumina Genome Analyzer II and lllumina HiSeq platforms.
One major advantage of using GCF is the use of robotics in the facility.
Samples will be barcoded and multiplexed with 24 samples sequenced
per lane for miRNA. We will use single-end sequencing and we expect
to achieve 20 million reads per sample.
miRNA expression in maternal serum and cord blood
The small RNA sequencing data will be analysed according to
a previously described protocol.25 Briefly, sequence adapters are
trimmed from the raw sequencing,17,26 trimmed reads are collapsed
into single unique reads,27 and collapsed reads along with their
total read counts, are aligned by using bowtie2.28 MicroRNA pro-
cessing variants (isomiRs) will be detected by using SeqBuster.29
The calcNormFactors function from the Bioconductor package
edgeR will be used to compute sample-specific normalization fac-
tors based on reads mapping to the spike-in RNAs.30 The
Bioconductor package limma combined with the voom transfor-
mation will be used to create miRNA expression profiles and
detect differentially expressed miRNAs and isomiRs.31,32
miRNA expression in placenta tissue
The placenta samples to be used in this study are formalin
fixed and paraffin embedded (FFPE). Given that miRNA expres-
sion profiles from frozen and FFPE samples are highly correlated,
we expect the miRNA profiles from these samples to be represen-
tative of the original placentas. In our hospital, formalin-fixed and
paraffin embedded placenta samples were analyzed with the qPCR
technique, and phenotypes of preeclampsia were identified by the
miRNA expression.
Overall goal and study aims
Epigenetic regulation of gene expression may be involved in
the developmental origins of health and disease (DOHaD).33 The
overall goal of this pilot project is to evaluate the integrity of our
samples, optimize our approach and test the feasibility of a larger
five-year project. The research aims of the current pilot study are
the following ones.
Aim 1
To investigate the intra-individual stability of miRNA expres-
sion profiles in maternal serum samples at four gestational time-
points (weeks 17, 25, 33 and 37), and in the corresponding cord
blood sample at birth (5 samples for each mother-child pair; n=60
samples from 12 mother-child pairs)
Aim 2
To test the integrity of our placenta samples using four samples
from four discrete regions of one placenta from one mother. 
Aim 3
To obtain an overview of the data accounting for possible differen-
tial miRNA expression profiles across sample type (serum and cord
blood) and over time (gestational weeks 17, 25, 33, 37, birth) in high-
and low-risk mothers, across SGA and non-SGA birth.
Aim 4
To observe maternal serum concentrations of EDCs at gesta-
tional week 17 in relation to repeated measures of miRNA.
Statistical analysis
For the purpose of the pilot, we will conduct an exploratory
factorial analysis to describe variability among correlated variables
with the ultimate aim being variable reduction based on interde-
pendencies between observations. The larger 5-year project will
include 1009 mother-child pairs. The statistical approach for the
larger project will consider results from this pilot study. 
Ethics
All participants provided informed written consent to partici-
pate in the SGA study. In 2012, renewed consent for continued use
of bio-samples was sought, and research ethics approval for use of
these samples was granted until June 2020 (2014/496/REK midt).
The current ethics approval includes this pilot project, and the larg-
er 5-year project provided bio-samples are analysed before June
2020, after which time new consent will be needed. The bio-sam-
ples for mothers who have not provided renewed consent are not
available for continued analysis. After June 2020, any unused bio-
samples will be destroyed in accordance with Institutional and
National biobanking regulations. 
Discussion and Conclusions
Endocrine disrupting chemicals (EDCs) such as synthetic pes-
ticides, metals, or contaminants in food, place the mother and fetus
at high risk of environmental injury during the prenatal period.
Maternal exposure to EDCs is known to result in abnormal fetal
growth patterns, later neurodevelopmental delays in children, and
may increase susceptibility to non-communicable diseases later in
life.7,8 Molecular fingerprints from EDCs and resulting epigenetic
modifications can be observed via miRNA expression profiles.
The overall goal of this pilot study is to evaluate the integrity
of our samples, optimize our approach and test the feasibility of a
larger five-year project. In so doing, we will refine our operations
including sample selection, laboratory methods, bioinformatics
pipeline, and overall organization for the larger cohort-wide analy-
sis. Our sample size for the current pilot study is limited to 12
mother child-pairs with maternal serum samples from four gesta-
tional time-points, and corresponding cord blood sample. We rec-
ognize that we lack statistical power to provide definitive conclu-
sions on associations between exposure and outcome. However,
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our observations will provide some overview of the data including
sample integrity, and some measures of reproducibility that would
need to be validated in the larger cohort of 1009 mother-child
pairs. Moreover, results from this pilot study may provide us an
indication of biological significance that may further help us with
temporal sample selection for the cohort-wide study. Given our
repeated measures (five samples for each pair) and the sophistica-
tion of our laboratory methods, the cost of the analysis was also a
factor in selecting a sample size of 12 mother-child pairs. 
In addition to maternal serum and corresponding cord blood,
we also have placenta tissue samples available for analysis. These
historic samples are FFPE fixed and have been stored at room tem-
perature for many years. The integrity of these samples, and our
ability to extract RNA from these samples is unknown. For each
mother we have four tissue samples, each from a distinct region of
the placenta. Given the anatomical and functional heterogeneity of
this organ,34 four tissue samples per placenta are required to gen-
erate representative data.16 We therefore anticipate that miRNA
expression from different regions of the same placenta will provide
us more information than single samples from multiple partici-
pants. With careful use of finite biological material, we have an
unprecedented opportunity to study the intergenerational impact of
epigenetic modifications throughout pregnancy, and across sample
types. This pilot study is longitudinal from both intra-individual
and inter-generational perspectives. Results from this pilot study
will form the basis for a larger 5-year project proposal with a focus
on neuro- and metabolic development of offspring in relation to
environmental exposures during pregnancy.
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